US · HCA · MEDICAL - CARE FACILITIES
HCA Healthcare, Inc. (HCA) intrinsic value and stock valuation
$475.57as of 2026-11-21 · Mkt cap 88.69B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
HCA Healthcare, Inc. DCF and intrinsic value
InvestorsCraft values HCA with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from HCA’s statements →
HCA Healthcare, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Pfizer Inc. (PFE) $27.40
- Bristol-Myers Squibb Company (BMY) $58.80
- Stryker Corporation (SYK) $310.00
- CVS Health Corp. (CVS) $80.84
- Vertex Pharmaceuticals Incorporated (VRTX) $515.02
- Medtronic plc (MDT) $99.94
- GSK plc (GSK) $47.76
- McKesson Corporation (MCK) $1,069.43
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $75.6B | $70.6B | $65B | $60.2B | $58.8B |
| Operating income | $12B | $10.5B | $9.63B | $9.05B | $9.68B |
| Net income | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B |
| EPSd | $29.4M | $22M | $19M | $19.2M | $21.2M |
| Operating cash flow | $12.6B | $10.5B | $9.43B | $8.52B | $8.96B |
| Capital expenditure | -$-4.94B | -$-4.88B | -$-4.74B | -$-4.4B | -$-3.58B |
| Free cash flow | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B |
| Total assets | $60.7B | $59.5B | $56.2B | $52.4B | $50.7B |
| Total debt | $50.2B | $45.2B | $41.9B | $40.2B | $36.7B |
| Net debt | $49.2B | $43.3B | $40.9B | $39.3B | $35.3B |
| Total equity | -$-2.77B | $555M | $1.06B | -$-73M | $1.49B |
| Cash and short-term investments | $1.04B | $2.02B | $935M | $908M | $1.45B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $75.6B | $70.6B | $65B | $60.2B | $58.8B |
| Cost of revenue | $44.2B | $41.9B | $39.4B | $37.1B | $36.3B |
| Gross profit | $31.4B | $28.7B | $25.6B | $23.2B | $22.5B |
| Research and development expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Selling, general and administrative expenses | $8B | $31.2B | $29.5B | $27.7B | $26.8B |
| Other expenses | $11.4B | -$-13.04B | -$-13.54B | -$-13.56B | -$-13.97B |
| Operating expenses | $19.4B | $18.1B | $16B | $14.1B | $12.8B |
| Cost and expenses | $63.6B | $60.1B | $55.3B | $51.2B | $49.1B |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $2.25B | $2.06B | $1.94B | $1.74B | $1.53B |
| Depreciation and amortization | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B |
| Ebitda | $15.6B | $13.9B | $12.7B | $13.3B | $14.3B |
| Operating income | $12B | $10.5B | $9.63B | $9.05B | $9.68B |
| Total other income/expenses, net | -$-2.13B | -$-2.02B | -$-1.92B | -$-473M | $155M |
| Income before tax | $9.83B | $8.52B | $7.71B | $8.58B | $9.83B |
| Income tax expense | $2.05B | $1.87B | $1.62B | $1.75B | $2.11B |
| Net income | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B |
| Weighted average shares outstanding | $230.7M | $258.6M | $272.4M | $290.4M | $323.3M |
| Weighted average diluted shares outstanding | $230.7M | $261.8M | $276.4M | $294.7M | $328.8M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.04B | $2.02B | $935M | $908M | $1.45B |
| Net receivables | $10.9B | $10.8B | $9.96B | $8.89B | $8.1B |
| Inventory | $1.65B | $1.74B | $2.02B | $2.07B | $1.99B |
| Total current assets | $13.6B | $16.4B | $14.9B | $13.6B | $13.5B |
| Property, plant and equipment, net | $31.1B | $31.5B | $29.9B | $27.6B | $26.2B |
| Goodwill and intangible assets | $10.3B | $10.1B | $9.95B | $9.65B | $9.54B |
| Long-term investments | $633M | $1.23B | $1.23B | $1.2B | $886M |
| Total non-current assets | $47.2B | $43.1B | $41.3B | $38.8B | $37.2B |
| Total assets | $60.7B | $59.5B | $56.2B | $52.4B | $50.7B |
| Accounts payable | $4.66B | $4.28B | $4.23B | $4.24B | $4.11B |
| Short-term debt | $6.74B | $5.04B | $2.79B | $734M | $629M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $16.4B | $15.2B | $12.7B | $9.9B | $9.58B |
| Long-term debt | $43.5B | $40.2B | $39.1B | $39.5B | $36.1B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $47.1B | $43.8B | $42.5B | $42.6B | $39.7B |
| Capital lease obligations | $1.85B | $2.21B | $2.27B | $2.7B | $2.72B |
| Total liabilities | $63.5B | $59B | $55.2B | $52.5B | $49.3B |
| Common stock | $2M | $3M | $3M | $3M | $3M |
| Retained earnings | -$-5.72B | -$-2.12B | -$-1.35B | -$-2.28B | -$-532M |
| Accumulated other comprehensive income (loss) | -$-305M | -$-387M | -$-425M | -$-490M | -$-404M |
| Total equity | -$-2.77B | $555M | $1.06B | -$-73M | $1.49B |
| Total investments | $633M | $1.32B | $1.23B | $1.2B | $886M |
| Total debt | $50.2B | $45.2B | $41.9B | $40.2B | $36.7B |
| Net debt | $49.2B | $43.3B | $40.9B | $39.3B | $35.3B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $6.78B | $6.66B | $5.24B | $6.83B | $7.72B |
| Depreciation and amortization | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B |
| Stock-based compensation | $0.00 | $360M | $0.00 | $341M | $440M |
| Change in working capital | $728M | -$-106M | -$-457M | -$-1.15B | -$-503M |
| Accounts receivable | -$-94M | -$-799M | -$-935M | -$-797M | -$-962M |
| Inventory | -$-154M | $334M | -$-126M | -$-59M | -$-540M |
| Accounts payable | $666M | $359M | $604M | -$-296M | $999M |
| Net cash provided by operating activities | $12.6B | $10.5B | $9.43B | $8.52B | $8.96B |
| Investments in property, plant and equipment | -$-4.94B | -$-4.88B | -$-4.74B | -$-4.4B | -$-3.58B |
| Acquisitions, net | -$-128M | $62M | -$-442M | $1.01B | $1.06B |
| Net cash used for investing activities | -$-4.99B | -$-4.93B | -$-5.32B | -$-3.39B | -$-2.64B |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-10.07B | -$-6.04B | -$-3.81B | -$-7B | -$-8.22B |
| Dividends paid | -$-679M | -$-690M | -$-661M | -$-653M | -$-624M |
| Net cash used for financing activities | -$-8.55B | -$-4.58B | -$-4.09B | -$-5.66B | -$-6.66B |
| Net change in cash | -$-893M | $998M | $27M | -$-543M | -$-342M |
| Cash at end of period | $1.04B | $1.93B | $935M | $908M | $1.45B |
| Operating cash flow | $12.6B | $10.5B | $9.43B | $8.52B | $8.96B |
| Capital expenditure | -$-4.94B | -$-4.88B | -$-4.74B | -$-4.4B | -$-3.58B |
| Free cash flow | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B |
Line items
Line items
Line items
About HCA Healthcare, Inc.
HCA Healthcare, Inc., operating through its subsidiaries, delivers a comprehensive array of healthcare services throughout the United States. The organization manages a network of general and acute care hospitals that provide a full spectrum of medical and surgical care, encompassing inpatient services, intensive care, cardiac treatment, diagnostic procedures, and emergency services. These hospitals additionally offer a broad range of outpatient care, such as ambulatory surgery, laboratory testing, radiology, respiratory therapy, cardiology, and physical therapy. Beyond its hospital infrastructure, HCA Healthcare operates numerous specialized outpatient facilities. These include standalone ambulatory surgery centers, dedicated emergency care facilities, urgent care clinics, walk-in clinics, advanced diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology treatment facilities, physician practices, and various other healthcare sites. Furthermore, the company oversees psychiatric hospitals, which offer diverse therapeutic programs. These services cater to child, adolescent, and adult psychiatric care, alongside adolescent and adult alcohol and drug abuse treatment and counseling. As of December 31, 2021, HCA Healthcare's extensive portfolio included 182 hospitals, specifically 175 general and acute care hospitals, five psychiatric hospitals, and two rehabilitation hospitals. Its network also featured 125 freestanding surgery centers and 21 freestanding endoscopy centers, all distributed across 20 states and England. Founded in 1968 and formerly known as HCA Holdings, Inc., the company's corporate headquarters are situated in Nashville, Tennessee.
- CEO
- Samuel N. Hazen
- Employees
- 320K
- Beta
- 1.13
Included in
Explore
Frequently asked questions
What is the intrinsic value of HCA Healthcare, Inc. (HCA)?
HCA Healthcare, Inc. (HCA) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is HCA undervalued?
HCA trades at a price of $475.57 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.